FOR IMMEDIATE RELEASE
Contact: Tim Bannon
Purdue Pharma L.P. Announces Agreement to End OxyContin® Patent Lawsuit with IMPAX Laboratories
IMPAX acknowledges validity, enforceability and infringement of Purdue Pharma’s OxyContin patents
Stamford, CT – April 2, 2007 – Purdue Pharma L.P. of Stamford, Connecticut and IMPAX Laboratories, Inc. of Hayward, California have agreed to end their lawsuit concerning certain Purdue Pharma patents on OxyContin® (oxycodone HCl controlled-release) Tablets. Under the terms of the settlement agreement, IMPAX Laboratories acknowledges that Purdue Pharma’s OxyContin patents are valid, enforceable and infringed by IMPAX’s extended-release oxycodone products and Purdue agrees it will not pursue damages against IMPAX for past infringement. Purdue also will grant a license to permit IMPAX (through its marketing partner, DAVA Pharmaceuticals) to keep its extended-release oxycodone products on the market through June 14, 2007, with rights to resume distribution in the future of a limited amount of product for a limited period of time.
The parties will be submitting the agreement to federal antitrust authorities for review and will also submit a consent judgment reflecting certain terms from the agreement to the federal district court in which the action was filed.
Purdue Pharma L.P. and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.
The professional product labeling for OxyContin® Tablets contains the following boxed warning:
Full prescribing information for OxyContin is available at
# # #